Quality adjusted survival analysis
- PMID: 2277877
- DOI: 10.1002/sim.4780091106
Quality adjusted survival analysis
Abstract
We present a technique, quality adjusted survival analysis, for the analysis of controlled trials where patients may experience several health states which differ in their quality of life. When the data are censored, a survival analysis of the quality adjusted life years achieved may involve informative censoring, and produce biased estimates. To overcome this, we partition the survival curve; the resulting areas, which represent the mean time in each state, are multiplied by utility weights to provide an unbiased estimate of (restricted) quality adjusted survival. If the appropriate weights are in doubt, the results are best presented as a threshold analysis over the utility weights, allowing individual recommendation to be read from a simple graph. The certainty of the conclusions can be presented as confidence bands on the threshold line. The techniques are illustrated with a re-analysis of a large three-arm trial of adjuvant chemoendocrine therapy for stage II breast cancer in postmenopausal women. This shows that if the value of time spent in toxicity is greater than the time spent in relapse, we can be 95 per cent confident that chemoendocrine therapy is the preferred option.
Similar articles
-
Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group.Control Clin Trials. 1993 Dec;14(6):485-99. doi: 10.1016/0197-2456(93)90029-d. Control Clin Trials. 1993. PMID: 8119064
-
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.Lancet. 1996 Apr 20;347(9008):1066-71. doi: 10.1016/s0140-6736(96)90277-9. Lancet. 1996. PMID: 8602056
-
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.J Clin Oncol. 1989 Jan;7(1):36-44. doi: 10.1200/JCO.1989.7.1.36. J Clin Oncol. 1989. PMID: 2642538 Clinical Trial.
-
Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.Lancet. 2001 Jul 28;358(9278):277-86. doi: 10.1016/S0140-6736(01)05483-6. Lancet. 2001. PMID: 11498214 Review.
-
Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.Pharmacoeconomics. 1993 Jul;4(1):40-66. doi: 10.2165/00019053-199304010-00006. Pharmacoeconomics. 1993. PMID: 10146967 Review.
Cited by
-
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.J Clin Oncol. 2009 Sep 10;27(26):4268-73. doi: 10.1200/JCO.2008.20.5815. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667274 Free PMC article.
-
Evaluating high dose therapy in Multiple Myeloma: use of quality-adjusted survival analysis.Qual Life Res. 2002 Mar;11(2):91-9. doi: 10.1023/a:1015096313594. Qual Life Res. 2002. PMID: 12018742 Clinical Trial.
-
Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data.Qual Life Res. 2006 Apr;15(3):411-23. doi: 10.1007/s11136-005-1579-7. Qual Life Res. 2006. PMID: 16547779 Review.
-
Net-benefit regression with censored cost-effectiveness data from randomized or observational studies.Stat Med. 2022 Sep 10;41(20):3958-3974. doi: 10.1002/sim.9486. Epub 2022 Jun 3. Stat Med. 2022. PMID: 35665527 Free PMC article.
-
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. Cochrane Database Syst Rev. 2022. PMID: 35170751 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical